Hormone Therapy Heart Study Finds No Added Risk

A new hormone therapy heart study is giving millions of midlife women a reason to breathe easier: modern menopause hormone treatment was not tied to more heart attacks, strokes, blood clots or early deaths. The research, announced Monday ahead of the American Heart Association's Scientific Sessions in Chicago, followed more than fifty-two thousand women in Israel.

What the researchers actually did

According to the American Heart Association, the team used records from Clalit Health Services to study fifty-two thousand three hundred thirty women between forty-five and fifty-nine. None had a history of heart disease, blood clots or cancer when the study began.

Half of the women started hormone replacement therapy, mostly pills or skin patches. The other half had recently seen a gynecologist but never started it. The groups were matched on age, body mass index, blood pressure, cholesterol, diabetes, smoking and socioeconomic status, then tracked for an average of twelve years and up to twenty-three.

The lead researcher, Ronen Arbel of Clalit Health Services and Sapir College, said that concerns about the heart are one of the most common reasons women decline hormone therapy, and why some clinicians hesitate to offer it.

The numbers, in plain English

The gap between the two groups was tiny. About four point four percent of women on therapy had a heart attack, stroke or related heart disease, versus four point six percent of women who skipped it. Death before age eighty was one point three percent against one point two percent.

Blood clots matched almost perfectly, at point three three percent in both groups, which works out to one hundred seventy-four women on therapy and one hundred seventy-five off it. The results looked the same whether the hormones came as pills, patches or gel, according to the release.

Why this matters now

Hormone therapy has had a rough reputation for two decades. Earlier randomized trials suggested harm, but the AHA notes that much of that evidence came from older formulas, higher doses, and women who started long after menopause. Current guidance from the American College of Obstetricians and Gynecologists is to begin within ten years of menopause onset and before age sixty.

The regulatory picture has shifted too. In November last year the FDA removed the boxed warnings from hormone therapy products after reviewing current data, a move the AHA release describes as based on evidence that the treatment is not tied to higher risk of cardiovascular disease, breast cancer or dementia.

Stacey Rosen, a women's heart health specialist at Northwell Health who was not involved in the work, called the findings part of growing evidence that today's options may not raise the risk of heart disease, stroke or clots for healthy women who start around the time of menopause.

The fine print you should not skip

This is a research abstract, which means it has not been peer reviewed, and the AHA says the findings are preliminary until a full paper is published. It is also observational, so it cannot prove cause and effect. Women who choose therapy may differ in exercise, diet, symptom severity or other health factors that the records did not capture.

The study also grouped women by the first therapy they used, and it did not track later switches in type or dose. And the reassurance applies to healthy women who began treatment in midlife, not to everyone. Separate research keeps showing that risk can vary by delivery method and dose, so the picture is not one size fits all.

That nuance shows up elsewhere. A large Danish registry study in the BMJ, reported by Endocrinology Advisor, found that transdermal therapy was not linked to higher clot, stroke or heart attack risk overall, while some higher-dose oral regimens were.

What to take from it

If you are a parent, an aunt or a friend watching someone in perimenopause suffer through hot flashes and sleepless nights, this is a good moment to start a better conversation with a doctor. Nothing here replaces personal medical advice, and anyone with a history of heart disease, clots or cancer is outside what this study looked at.

The bigger story is a slow reset. A treatment once treated as a red flag is being re-examined with modern data, and women's midlife health is finally getting serious research attention. For more on health news, check the health section and the science desk.